Follow the Money: How Lobbying and Campaign Contributions Shape Food and Drug Policy

In 2014, a teenage programmer released a free browser extension that displayed, next to any politician’s name on a web page, how much money that politician had received from various industries. The tool went viral with headlines about exposing “sellout politicians.” Its premise was simple: voters should be able to see, at a glance, who funds the people making laws that affect their lives.

That premise matters for health. Decisions about drug prices, food labeling, pesticide approvals, soda taxes, and nutrition programs are shaped by evidence and also by lobbying and campaign money. This article examines what research shows about industry spending on health-related politics and science, how influence works, why the picture is more complicated than headlines suggest, and how anyone can track money in politics using free, nonpartisan tools.

How much do drug and health industries spend influencing policy? Enormous sums. The pharmaceutical and health products industry spent roughly $4.7 billion on federal lobbying from 1999 to 2018, more than any other industry, plus hundreds of millions in campaign contributions. This money funds lobbying, research framing, and payments to doctors. It does not simply “buy votes,” but it shapes which issues get attention and how policies are written, which is why following the money matters.

How Much Do Health Industries Spend on Lobbying?

The pharmaceutical and health products industry spent about $4.7 billion on federal lobbying from 1999 to 2018, more than any other industry, along with hundreds of millions in campaign contributions to influence policy. A 2020 study in JAMA Internal Medicine by Olivier Wouters of the London School of Economics analyzed federal and state data from two nonpartisan organizations that track political money. From 1999 to 2018, the pharmaceutical and health product industry recorded $4.7 billion in federal lobbying expenditures, an average of $233 million per year and more than any other industry. The industry’s main trade group accounted for 9 percent of that spending. The industry also contributed $414 million to presidential and congressional candidates, party committees, and outside spending groups, and $877 million to state candidates and committees, with nearly half going to California. Of the 20 senators and 20 representatives who received the most contributions, 39 belonged to committees with jurisdiction over health legislation, 24 in senior positions. Contributions spiked in years when state ballot measures on drug pricing were voted on.

How Does Industry Money Influence Science?

Industry funding can shape science by sponsoring favorable studies, funding research that frames issues advantageously, and supporting experts and organizations, which research shows can bias conclusions toward sponsors. Money shapes health policy through politics and also through the science that policymakers rely on. A 2016 analysis in JAMA Internal Medicine by Cristin Kearns, Laura Schmidt, and Stanton Glantz examined internal documents of the Sugar Research Foundation. In 1965 the foundation sponsored a literature review, published in the New England Journal of Medicine, that singled out dietary fat and cholesterol as causes of coronary heart disease and downplayed evidence implicating sugar. The foundation set the review’s objective, contributed articles for inclusion, and received drafts, but its funding and role were not disclosed. The authors concluded that the industry sponsored research in the 1960s and 1970s that successfully cast doubt on sugar’s hazards while promoting fat as the dietary culprit.

Funding bias appears in modern research as well. A 2007 study in PLOS Medicine by Lenard Lesser and colleagues analyzed 206 articles about soft drinks, juice, and milk. Among interventional studies, none of those fully funded by industry reached conclusions unfavorable to the sponsor, compared with 37 percent of studies with no industry funding. Articles with all industry funding had about 7.6 times the odds of reaching favorable conclusions. In an accompanying 2016 commentary in JAMA Internal Medicine, nutrition scholar Marion Nestle argued that the sugar documents show why industry funding of nutrition research remains a concern today.

What Is the Industry Influence Playbook?

Common tactics include funding friendly research, forming front groups, lobbying regulators and lawmakers, sponsoring patient and professional organizations, and emphasizing uncertainty to delay unfavorable rules. Researchers have compared tactics used by different industries facing health concerns. A 2009 analysis in the Milbank Quarterly by Kelly Brownell and Kenneth Warner reviewed decades of tobacco industry conduct, including its 1954 “Frank Statement to Cigarette Smokers” promising concern for public health, followed by decades of deception. They described a tobacco playbook that emphasized personal responsibility, funded scientists who produced favorable research, questioned unfavorable science, lobbied against regulation, and promoted voluntary self-regulation, and they examined how similar strategies appeared in parts of the food industry. The authors urged the food industry to learn from tobacco’s history rather than repeat it.

More recently, a 2025 paper in The Lancet by Phillip Baker and colleagues, the third in a series on ultra-processed foods, argued that leading ultra-processed food corporations and allied groups have used political influence, including lobbying, funding of research and professional organizations, and opposition to regulation, to shape food systems in favor of highly processed products. The authors called for global policy action modeled partly on tobacco control, while acknowledging the complexity of food systems and the need for evidence-based measures.

Influence Runs in Many Directions

Money in health politics is not limited to large corporations. Hospitals, insurers, physician groups, pharmacists, nurses’ unions, patient advocacy organizations, farm groups, organic and natural products associations, environmental groups, and public health organizations all lobby and, in many cases, make political contributions. On issues like GMO labeling, pesticide regulation, and raw milk, interests on multiple sides spend money to influence outcomes. Some patient advocacy groups receive substantial funding from drug companies, which can shape their positions. Recognizing that influence comes from many directions helps people evaluate claims critically rather than assuming that only one side is motivated by money.

Does Lobbying Money Actually Buy Votes?

Money rarely buys votes outright, but it buys access and influence, shaping which issues get attention, how bills are written, and which experts and arguments lawmakers hear, in subtler but real ways. Research on whether campaign contributions change how legislators vote is mixed. Contributions often flow to legislators who already support a donor’s positions, making it difficult to distinguish influence from alignment. Political scientists generally find that money buys access, the opportunity to meet with legislators and their staff and to shape details of legislation, more reliably than it changes votes on high-profile issues. Lobbying, which often involves technical expertise and long-term relationships, may shape regulations and bill language in ways that are less visible to the public. The concentration of health industry contributions among members of health committees, documented in the Wouters study, is consistent with efforts to gain access to those with the most influence over health policy.

Free Tools to Follow the Money

Tool	What it shows
OpenSecrets	Federal campaign contributions and lobbying by industry, organization, and politician
Federal Election Commission data	Official filings of contributions and spending by federal candidates and committees
Lobbying Disclosure Act reports	Quarterly federal lobbying reports listing clients, issues, and amounts
State campaign finance databases	State-level contributions and ballot measure spending
Open Payments	Payments from drug and device companies to physicians and teaching hospitals

Do Drug Companies Pay Doctors?

Yes. Drug and device companies make large payments to physicians for consulting, speaking, meals, and research, which are disclosed in public databases and have been linked to prescribing patterns. Industry money also flows to health care professionals. Under the federal Open Payments program, created by the Affordable Care Act, drug and medical device companies must report payments and gifts to physicians and teaching hospitals, including speaking fees, consulting fees, meals, and travel. The data are publicly searchable, allowing patients to see whether their doctors have received industry payments. Studies have found associations between receiving payments, even small ones like meals, and prescribing patterns that favor the paying company’s products. Receiving payments does not mean a doctor is acting improperly, but transparency helps patients ask informed questions.

Food and Farm Policy

Food and agricultural policy is shaped by intense lobbying. The Farm Bill, renewed every few years, governs crop subsidies, conservation programs, and the Supplemental Nutrition Assistance Program, and attracts lobbying from commodity groups, food manufacturers, retailers, anti-hunger organizations, and environmental groups. Debates over soda taxes, restrictions on purchasing sugary drinks with SNAP benefits, front-of-package labeling, school meal standards, and food dyes involve spending by beverage and food companies as well as by public health advocates. Knowing who funds which side helps people evaluate arguments in these debates.

Drug Pricing and Health Reform

Drug pricing has been one of the most heavily lobbied health issues. The industry has spent heavily on federal lobbying and on state ballot measures concerning drug prices, as the Wouters study documented. Other stakeholders, including insurers, hospitals, employers, and patient groups, also lobby on these issues, sometimes on opposing sides. Understanding these dynamics helps explain why health reforms often take years to pass and why final legislation may differ from initial proposals.

How to Evaluate Health Claims in Political Debates

When politicians, advocacy groups, or industry representatives make health claims, ask: Who funded the research being cited? Is the research peer-reviewed and replicated? Do independent scientific bodies agree? Who funds the organization making the claim? What do groups with different funding sources say? These questions apply to all sides, including corporations, advocacy organizations, and alternative health groups. Transparency about funding does not automatically discredit an argument, but it provides context for evaluating it.

Transparency and Reform

Policy proposals to reduce undue influence include stronger lobbying disclosure, limits on campaign contributions, public financing of elections, stricter conflict-of-interest rules for scientific advisory committees, and requirements that researchers disclose funding and sponsors’ roles. Scientific journals have adopted disclosure requirements, and some public health organizations refuse funding from industries whose products they study. Views on campaign finance reform vary widely across the political spectrum, with debates involving free speech, fairness, and the role of money in democracy.

What Citizens Can Do

Look up your representatives’ top donors and lobbying contacts using public databases. Read beyond headlines on health policy debates and check who funds the organizations involved. Participate in public comment periods on health and food regulations, which agencies are required to consider. Contact elected officials about issues you care about; constituent communication remains influential. Support independent research and journalism. Vote in primary and general elections, including for state and local offices where much health policy is made.

The Browser Extension That Started a Conversation

The 2014 browser extension that inspired this article highlighted names of members of Congress on any web page and, when users hovered over them, displayed the share of their campaign funding from different industries and from small donors. It drew media attention because it put campaign finance data in front of people while they read news, rather than requiring them to visit a separate database. Similar tools and apps have since appeared, and campaign finance data are now widely integrated into news coverage. The idea that voters should be able to see who funds their representatives as easily as they read the news remains appealing across the political spectrum.

Limits of Campaign Finance Data

Campaign finance data have limitations. Contributions are often categorized by the donor’s employer, which may not reflect the donor’s personal views or the company’s interests. Spending by some outside groups does not have to disclose donors fully. Lobbying reports describe issues in general terms and may not reveal specific positions. And industry categories can lump together companies with different interests. Users of these tools should treat the data as one piece of context rather than proof of corruption.

Scientific Advisory Committees

Federal agencies rely on advisory committees of outside experts to review drugs, vaccines, dietary guidelines, and pesticides. Conflicts of interest among committee members have long been a concern. Agencies require members to disclose financial ties and may grant waivers allowing participation despite conflicts. Studies of FDA advisory committees have found that members with financial ties to sponsors were somewhat more likely to vote in sponsors’ favor, though such conflicts rarely changed overall outcomes. Strong conflict-of-interest rules and transparency about waivers help maintain trust in these committees.

The Revolving Door

Influence also flows through people. Former regulators, congressional staff, and members of Congress often take jobs with industries they once oversaw, and industry employees sometimes move into government roles. Supporters argue that this exchange brings valuable expertise to both sectors. Critics argue that it can create conflicts of interest, as officials may favor future employers or former colleagues. Ethics rules impose waiting periods before former officials can lobby their old agencies, but these rules vary in strength and enforcement. Public databases and news reporting track many of these career moves.

Ballot Measures and State Politics

Some of the largest health-related political spending occurs on state ballot measures, where voters decide issues directly. Measures on drug pricing, soda taxes, GMO labeling, dialysis clinic regulations, and tobacco taxes have drawn tens of millions of dollars in spending by industries and advocacy groups. The Wouters study found spikes in pharmaceutical industry contributions in years when key state drug pricing measures were on the ballot. Because ballot measure campaigns rely heavily on advertising, voters benefit from checking who funds the committees behind ads, which state disclosure laws generally require.

Patient Advocacy Groups and Industry Funding

Patient advocacy organizations play important roles in raising awareness, funding research, and representing patients in policy debates. Many receive funding from pharmaceutical and device companies, sometimes a substantial share of their budgets. Studies have found that such funding is common and not always disclosed clearly. Industry funding does not mean an organization’s positions are wrong, but it can influence priorities, for example on drug pricing or coverage of specific treatments. Checking an organization’s funding disclosures helps patients and policymakers interpret its advocacy.

Looking Ahead

Transparency tools continue to evolve, with campaign finance and lobbying data increasingly integrated into news coverage, browser tools, and artificial intelligence assistants. Debates over drug prices, food additives, ultra-processed foods, and agricultural chemicals are likely to remain heavily lobbied. Greater public awareness of who funds political and scientific activity, combined with rules that require disclosure, can help ensure that health policy reflects evidence and public interest as well as the interests of those with the most money to spend.

Pesticide and Agricultural Chemical Policy

Decisions about pesticide registrations, such as those involving glyphosate, dicamba, and chlorpyrifos, are shaped by scientific review, litigation, and lobbying. Agricultural chemical companies, farm groups, environmental organizations, farmworker advocates, and organic industry groups all engage in these debates and make political contributions. Because regulatory decisions can affect billions of dollars in sales and the health of workers and communities, they attract sustained lobbying at federal and state levels. Following the money on these issues helps explain why pesticide policy often swings with changes in administration and why court challenges are common.

Dietary Guidelines and Industry Input

The Dietary Guidelines for Americans, updated every five years, influence school meals, federal nutrition programs, and food labeling. Industries with stakes in the recommendations, including meat, dairy, sugar, beverage, and grain producers, have long sought to shape them through public comments, lobbying, and funding of research cited in reviews. Advisory committee members must disclose conflicts of interest, and the process has faced criticism from multiple directions regarding transparency and the role of industry. Understanding these dynamics helps explain why guidelines sometimes appear to soften recommendations on specific foods.

Media Literacy and Health Information

The same critical thinking that applies to political money applies to health information online. Websites, influencers, and organizations promoting health products or causes may have financial interests, including affiliate commissions, product sales, or sponsorships. Asking who benefits from a particular message, whether it comes from a corporation, a supplement seller, or an advocacy group, helps readers evaluate claims. Reliable health information cites peer-reviewed evidence, discloses funding and relationships, and acknowledges uncertainty and opposing views.

Why Transparency Has Bipartisan Appeal

Concern about money in politics crosses party lines. Voters across the political spectrum express worry that wealthy interests have too much influence, though they may disagree about which interests and what to do about it. Some emphasize corporate influence, others emphasize the influence of unions, advocacy groups, or wealthy individual donors. Disclosure, which lets voters see who funds whom without restricting speech, has historically drawn broader support than limits on contributions or spending. Tools that make disclosed information easy to access serve voters regardless of their political views.

Questions to Ask About a Health Policy Debate

Who would gain or lose financially from the proposed policy? Which organizations are lobbying on each side, and who funds them? What does independent research, not funded by interested parties, show? Have scientific bodies without financial stakes weighed in? Are claims about costs or health effects backed by evidence? Asking these questions helps cut through advertising and talking points to the substance of a debate.

A Balanced View

Research documents large political spending by health industries, with the pharmaceutical and health product industry spending more on federal lobbying than any other sector and concentrating contributions among legislators who oversee health policy. Historical documents show that industry funding has shaped nutrition science, and modern studies find funding associated with favorable conclusions. At the same time, influence comes from many directions, contributions do not necessarily buy votes, and campaign finance data have limitations. Transparency tools give citizens a way to see these relationships and weigh arguments in health debates more critically.

Practical Takeaways

Use free databases to see who funds your elected officials and who lobbies on health issues. Check funding sources behind health studies and advocacy campaigns, on all sides. Look up whether your doctor has received industry payments through Open Payments if you are curious. Participate in public comment periods and contact your representatives on health issues. Support transparency rules for research, lobbying, and advisory committees.

Common Myths

“Campaign contributions always buy votes.” Research suggests money more reliably buys access than specific votes, and contributions often go to legislators already aligned with donors.

“Only big corporations lobby on health.” Hospitals, unions, advocacy groups, farm organizations, and public health groups also lobby.

“Industry-funded research is always wrong.” Funding is associated with favorable conclusions, but each study should be evaluated on its methods and replication.

“Political money data are secret.” Much of it is publicly available through government filings and nonpartisan databases.

“Nothing can be done.” Public comments, constituent contact, voting, and transparency rules all influence policy.

Key Terms

Lobbying: Efforts to influence legislation or regulation, often by paid professionals.

Campaign contribution: Money given to candidates, parties, or political committees.

Conflict of interest: A situation in which financial or other interests could influence professional judgment.

Open Payments: A federal database of industry payments to physicians and teaching hospitals.

Outside spending: Political spending by groups independent of candidates’ campaigns.

The Bottom Line

A teenager’s 2014 browser extension that showed politicians’ funding sources captured a widely shared concern: money influences health policy. Research confirms that the pharmaceutical and health product industry spent $4.7 billion on federal lobbying from 1999 to 2018, more than any other industry, and that its contributions concentrated among legislators overseeing health legislation. Industry funding has also shaped nutrition science, from the sugar industry’s 1960s research to modern beverage studies. Influence comes from many sides and does not always change votes, but transparency tools let anyone follow the money and evaluate health debates more critically.

Frequently Asked Questions

How much does the drug industry spend on lobbying?

The pharmaceutical and health products industry is the largest lobbying spender in the United States, investing roughly $4.7 billion on federal lobbying from 1999 to 2018, more than any other industry. On top of this, it contributes hundreds of millions of dollars to political campaigns. This spending funds efforts to influence legislation, regulation, drug pricing, and other policies affecting the industry’s interests.

Does lobbying money actually change laws?

Lobbying rarely “buys” a vote outright, but it buys access and influence in subtler ways. Money helps determine which issues lawmakers prioritize, how bills are drafted, which experts and arguments they hear, and whether unfavorable regulations are delayed or weakened. Over time, sustained spending can shape the policy environment significantly, even if no single contribution directly flips a vote, which is why the scale of health-industry spending matters.

How does industry money affect medical research?

Industry funding can influence research in several ways. Studies with financial ties to a sponsor are more likely to report conclusions favorable to that sponsor, through study design, selective publication, and framing, even when individual scientists act honestly. Companies may also fund research that emphasizes uncertainty about risks. This is why disclosure of funding and conflicts of interest, and replication by independent researchers, are so important.

Can I find out if my doctor takes money from drug companies?

Yes. In the United States, the Open Payments database, run by the federal government, discloses payments that drug and medical device companies make to physicians and teaching hospitals, including for consulting, speaking, meals, travel, and research. You can search it for free by a doctor’s name. Research has linked such payments to prescribing patterns, so this transparency tool helps patients understand potential influences on their care.

How can I follow the money in health policy myself?

Several free tools let you track health-industry money. OpenSecrets.org reports lobbying spending and campaign contributions by industry and company. The federal Open Payments database shows payments to doctors. Government lobbying disclosure sites list registered lobbyists and their clients. Using these resources, you can see which companies spend the most, which lawmakers receive contributions, and how financial interests may intersect with health policy decisions.

References

1. Wouters OJ. Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999–2018. JAMA Internal Medicine. 2020;180(5):688–697. PMID 32125357
2. Kearns CE, Schmidt LA, Glantz SA. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Internal Medicine. 2016;176(11):1680–1685. PMID 27617709
3. Nestle M. Food Industry Funding of Nutrition Research: The Relevance of History for Current Debates. JAMA Internal Medicine. 2016;176(11):1685–1686. PMID 27618496
4. Lesser LI, Ebbeling CB, Goozner M, et al. Relationship between funding source and conclusion among nutrition-related scientific articles. PLOS Medicine. 2007;4(1):e5. PMID 17214504
5. Brownell KD, Warner KE. The perils of ignoring history: Big Tobacco played dirty and millions died. How similar is Big Food? Milbank Quarterly. 2009;87(1):259–294. PMID 19298423
6. Baker P, Slater S, White M, et al. Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response. Lancet. 2025;406(10520):2703–2726. PMID 41270764

Last updated: October 6, 2026